4.3 Review

Beta-Secretase: Structure, Function, and Evolution

期刊

CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
卷 7, 期 3, 页码 278-294

出版社

BENTHAM SCIENCE PUBL
DOI: 10.2174/187152708784936626

关键词

BACE-1; Secretase; Memapsin; Alzheimer; Amyloid; Aspartyl protease

资金

  1. NIA NIH HHS [R01 AG023055-02, R01 AG023055-01A1, R01 AG022103, AG022103, R01 AG023055-03, R01 AG023055-05, R01 AG023055, R01 AG023055-04, AG023055] Funding Source: Medline
  2. NATIONAL INSTITUTE ON AGING [R01AG023055, R01AG022103] Funding Source: NIH RePORTER

向作者/读者索取更多资源

The most popular current hypothesis is that Alzheimer's disease (AD) is caused by aggregates of the amyloid peptide (A beta) which is generated by cleavage of the A beta protein precursor (APP) by beta-secretase (BACE-1) followed by gamma-secretase. BACE-1 cleavage is limiting for the production of A beta making it a particularly good drug target for the generation of inhibitors that lower A beta. A landmark discovery in AD was the identification of BACE-1 (a.k.a. Memapsin-2) as a novel class of type I transmembrane aspartic protease. Although BACE-2, a homologue of BACE-1, was quickly identified, follow up studies using knockout mice demonstrated that BACE-1 was necessary and sufficient for most neuronal A beta generation. Despite the importance of BACE-1 as a drug target, development has been slow due to the incomplete understanding of its function and regulation and the difficulties in developing a brain penetrant drug that can specifically block its large catalytic pocket. This review summarizes the biological properties of BACE-1 and attempts to use phylogenetic perspectives to understand its function. The article also addresses the challenges in discovering a selective drug-like molecule targeting novel mechanisms of BACE-1 regulation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据